Cellular immunotherapy and autologous transplantation for hematologic malignancy

Immunological Reviews

Volumn 157, Issue , 1997, Pages 231-240

  Margolin, Kim A ^a   Negrin, Robert S ^b   Wong, Kamehameha K ^a   Chatterjee, Saswati ^a   Wright, Christine ^a   Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; AUTOTRANSPLANTATION; EFFECTOR CELL; GENE TRANSFER; GENETICS; IMMUNOTHERAPY; KILLER CELL; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY;

EID: 0030754896     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb00986.x     Document Type: Review

References (83)

1. Rosenberg SA. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. In: DeVita, VT Jr, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: J.B. Lippincott Company; 1986. p. 55-91.
2. Foa R. Does interleukin-2 have a role in the management of acute leukemia? J Clin Oncol 1993;11:1817-1825.
3. Sznol M, Parkinson DR. Interleukin-2 in therapy of hematologic malignancies. Blood 1994;83:2020-2022.
4. Dawson MM, Johnston D, Taylor GM, Moore M. Lymphokine activated killing of fresh human leukaemias. Leuk Res 1986;10:683-688.
5. Oshimi K, et al. Cytotoxicity of interleukin-2-activated lymphocytes for leukemia and lymphoma cells. Blood 1986;68:938-948.
6. Fierro MT, et al. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 1988;2:50-54.
7. Lotzova E, Savary CA, Herberman RB. Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. Leuk Res 1987;11:1059-1066.
8. Lista P, et al. Lymphokine-activated killer (LAK) cells inhibit the clonogenic growth of human leukaemic stem cells. Eur J Haematol 1989;42:425-430.
9. Foa R, et al. Interleukin-2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin. Br J Haematol 1990;75:34-40.
10. Gottlieb DJ, et al. A phase I clinical trial of recombinant interleukin-2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br J Cancer 1989;60:610-615.
11. Foa R, et al. Treatment of acute leukemia in patients with recombinant interleukin 2: a pilot study. Br J Haematol 1991;77:491-496.
12. Maraninchi D, et al. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 1991;78:2182-2187.
13. Meloni G, et al. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study. Leukemia 1992;6:780-785.
14. Gottlieb DJ, et al. Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. Br J Haematol 1990;75:499-505.
15. Long GS, Cramer DV, Harnaha JB, Hiserodt JC. Lymphokine activated killer (LAK) cell purging of leukemic bone marrow: range of activity against different hematopoietic neoplasms. Bone Marrow Transplant 1990;6:169-177.
16. Schlegel PG, Schmidt-Wolf G, Schmidt-Wolf IGH, Kwak LW, Chao NJ. Lymphokine-activated killer cell activity against autologous lymphoma cells following bone marrow transplantation. Cancer Res Ther Control 1993;3:145-152.
17. Klingemann H-G, Deal H, Reid D, Eaves CJ. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts. Exp Hematol 1993;21:1263-1270.
18. Agah R, Malloy B, Kerner M, Mazumder A. Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs tumor effector in transplantation. J Immunol 1989;143:3093-3099.
19. Agah R, et al. Potent graft antitumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin-2-activated syngeneic bone marrow in mice. Cancer Res 1989;49:5959-5963.
20. Charak BS, Brynes RK, Groshen S, Chen S C, Mazumder A. Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 1990;76:2187-2190.
21. Charak BS, Brynes RK, Katsuda S, Groshen S, Chen S-C, Mazumder A. Induction of graft versus leukemia effect in bone marrow transplantation: dosage and time schedule dependency of interleukin 2 therapy. Cancer Res 1991;51:2015-2020.
22. Charak BS, Malloy B, Agah R, Mazumder A. A novel approach to purging of leukemia by activation of bone marrow with interleukin-2. Bone Marrow Transplant 1990;6:193-198.
23. Margolin KA, Wright C, Forman SJ. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells. Leukemia (In press).
24. Gambacorti-Passerini C, et al. Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes. Cancer Res 1988;48:2372-2376.
25. Beunyunes MC, et al. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993;12:159-163.
26. Benyunes C, et al. Immunotherapy with IL-2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant 1995;16:283-288.
27. Rosenberg SA, et al. Use of minor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma; a preliminary report. N Engl J Med 1988;319:1676-1680.
28. Ochoa AC, Gromo G, Alter BJ, Sondel PM, Bach FH. Long-term growth of LAK cells: role of anti-CD3, β-IL-1, interferon-γ and β. J Immunol 1987;138:2728-2733.
29. Schmidt-Wolf IGH, Negrin RS, Kiem H, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991;174:139-149.
30. Schmidt-Wolf IGH, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine induced killer cells. Exp Hematol 1993;21:1673-1679.
31. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994;153:1687-1696.
32. Schmidt-Wolf IGH, et al. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol 1995;169:85-90.
33. Scheffold C, et al. Potential of autologous immunologic effector cells for bone marrow purging in patients with chrome myeloid leukemia. Bone Marrow Transplant 1995;15:33-39.
34. Schmidt RE, Murray C, Daley JF, Schlossman SF, Ritz J. A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med 1986;164:351-356.
35. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986;136:4480-4486.
36. + cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression. Cell Immunol 1991;136:486-495.
37. + cells derived from T cells. Blood 1996;88(Suppl 1):316(Abstract).
38. + T cells: role of endogenous IL-12 and monocyte-derived contact-dependent factor. (Submitted)
39. Bosma GC, Custer RP, Bosma JM. A severe combined immunodeficiency mutation in the mouse. Nature 1983;301:527-530.
40. Uckun FM. Severe combined immunodeficient mouse models of human leukemia. Blood 1996;88:1135-1146.
41. Negrin RS, Kiem HP. Schmidt-Wolf IGH, Blume KG, Cleary ML. Detection of minimal residual disease using the polymerase chain reaction following bone marrow purging. Blood 1991;77:654-660.
42. BCR ABL protein. Proc Natl Acad Sci USA 1992;89:1468-1472.
43. Cullis JO, Barret AJ, Goldman JM, Lechler RI. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines. Leukemia 1994;8:165-170.
44. Bocchia M, et al. Specific binding of leukemia oncogene fusion protein peptides to HLA Class I molecules. Blood 1995;85:2680-2684.
45. Bocchia M, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996;9:3588-3592.
46. Greco G, et al. Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 1996;10:693-699.
47. BCR ABL protein by human T cells. Leukemia 1995;9:1344-1348.
48. + T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 1996;88:3522-3527.
49. MacIntyre AR, Christmas SE, Clark RE. The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide. Exp Hematol 1996;24:1307-1311.
50. Choudhury A, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997;89:1133-1142.
51. Steinmin RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-296.
52. Steinman RM. Dendritic cells and immune-based therapies. Exp Hematol 1996;24:859-862.
53. Shurin MR. Dendritic cells presenting tumor antigen. Cancer Immunol Immunother 1996;43: 158-164.
54. H2 immunity in neonatal mice. Science 1996;271:1728-1734.
55. Ridge JP, Fuchs EJ, Matzinger P. Neonatal tolerante revisited: turning on newborn T cells with dendritic cells. Science 1996;271:1723-1726.
56. Inaba K, Metlay JP, Crowley MT, Steinman RM. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, major histocompatibility complex-restricted T cells in situ. J Exp Med 1990;172:631-640.
57. Flamand V, et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994;24:605-610.
58. Mayordomo JI, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-1302.
59. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-287.
60. Zitvogel L, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
61. Mayordomo JI, et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996;183:1357-1365.
62. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156:2918-2926.
63. Hsu FJ, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58.
64. Kast WM, Boog CJP, Roep BO, Voordouw AC, Melief CJM. Failure or success of virus-specific cytotoxic T-lymphocyte response defects of dendritic cells. J Immunol 1988;140:3186-3193.
65. Hengel H, Linder M, Wagner H, Heeg K. Frequency of herpes simplex virus-specific murine cytotoxic T lymphocyte precursors in mitogen- and antigen-driven primary in vitro T cell response. J Immunol 1987;139:4196-4202.
66. Macatonia SE, Taylor PM, Knight SC, Askonas BA. Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. J Exp Med 1989;169:1255-1264.
67. + T cells. J Clin Invest 1994;94:797-807.
68. + cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int Immunol 1993;5:849-857.
69. Rouse RJ, Nair SK, Lydy SL, Bowen JC, Rouse BT. Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins. J Virol 1994;68:5685-5689.
70. Saikh KU, Martin JD, Nishikawa AH, Dillon SB. Influenza A virus-specific H-2d restricted cross-reactive cytotoxic T lymphocyte epitope(s) detected in the hemagglutinin HA2 subunit of A/Udorn/72. Virology 1995;214:445-452.
71. Romani N, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
72. Sadovnikova E, et al. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein. Int Immunol 1994;6:289-296.
73. Podsakoff G, Wong KK Jr, Chatterjee S. Stable and efficient gene transfer into non-dividing cells by adeno-associated virus (AAV)-based vectors. J Virol 1994;68:5656-5666.
74. Alexander IE, Russell DW, Miller AD. DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J Virol 1994;68:8282-8287.
75. Flotte TR, Afione SA, Zeitlin PL. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 1994;11:517-521.
76. Zeitlin PL, et al. Alveolar stem cell transduction by an adeno-associated viral vector. Gene Ther 1998;2:623-631.
77. Kaplitt MG, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994;8:148-153.
78. Du B, Wu P, Boldt-Houle DM, Terwilliger EF. Efficient transduction of human neurons: with an adeno-associated virus vector. Gene Ther 1996;3:254-261.
79. Chatterjee S, Wong KK, Podsakoff G, Zaia J, Forman SJ, Adeno-associated virus vectors for high efficiency gene transfer into primary human hematopoietic tells. Blood 1992;80:167(Abstract).
80. Chatterjee S, Wong KK Jr. Adeno-associated virus vectors for gene therapy of the hematopoietic system. Curr Top Microbiol Immunol 1996;218: 61-73.
81. Fisher-Adams G, Wong KK Jr, Forman S, Podsakoff GM, Chatterjee S. Integration of adeno-associated virus vector genomes in human CD34 cells following transduction. Blood 1996;88:492-504.
82. Zhou SZ, Broxmeyer HE, Cooper S, Harrington MA, Srivastava A. Adeno-assodated virus 2-mediated gene transfer in murine hematopoietic progenitor cells. Exp Hematol 1993;21:928-933.
83. Chatterjee S, Podsakoff G, Wong KK Jr. Gene transfer into terminally differentiated primary human peripheral blood-derived mononuclear cells by adeno-associated virus. Blood 1994;84:360(Abstract).